Clinical Significance of Tryptophan Metabolism in the Nontumoral Hemisphere in Patients with Malignant Glioma

David O. Kamson1,2, Tiffany J. Lee1, Kaushik Varadarajan1, Natasha L. Robinette3,4, Otto Muzik1–3,5, Pulak K. Chakraborty1,3, Michael Snyder4, Geoffrey R. Barger4,5, Sandeep Mittal4,6,7, and Csaba Juhász1,2,4,5

1 PET Center and Translational Imaging Laboratory, Children’s Hospital of Michigan, Detroit, Michigan; 2 Department of Pediatrics, Wayne State University, Detroit, Michigan; 3 Department of Radiology, Wayne State University, Detroit, Michigan; 4 Karmanos Cancer Institute, Detroit, Michigan; 5 Department of Neurology, Wayne State University, Detroit, Michigan; 6 Department of Neurosurgery, Wayne State University, Detroit, Michigan; and 7 Department of Oncology, Wayne State University, Detroit, Michigan

AMT (α-[11C]-methyl-L-tryptophan) is a radiotracer originally developed to assess brain serotonin synthesis using PET (1–4). Moreover, under pathologic conditions, AMT PET can also track upregulation of the immunosuppressive kynurenine pathway (leading to enhanced conversion of tryptophan to kynurenine metabolites) in tumor tissue and epileptic foci (4–8). Increased tumoral AMT uptake is a hallmark of grade III–IV gliomas (9,10) and is also a strong imaging marker of poor survival when detected after initial glioma treatment (surgery and chemoradiation) (11).

Although several amino acid PET tracers have been used to characterize brain tumors (9–13), only AMT PET has the additional ability to study extratumoral cerebral tryptophan metabolism and serotonergic abnormalities. In healthy adults, AMT PET studies of brain serotonin synthesis revealed some sex differences without a clear age effect (14–16). AMT PET has also been used to study focal and global serotonergic brain abnormalities in autism, migraine, and various psychiatric conditions (17–19). Until recently, however, no studies addressed potential abnormalities and clinical correlates of brain tryptophan metabolism in neuro-oncologic patients. Recently, our group reported decreased frontal cortical AMT uptake in treatment-naïve patients with brain tumors, as compared with healthy control subjects (20), but the potential clinical significance of extratumoral abnormalities of brain tryptophan uptake remained to be clarified.

In the present study, we assessed brain regional changes of AMT uptake in a large cohort of patients evaluated with gliomas. We hypothesized that cortical or thalamic AMT uptake contralateral to the glioma will be related to clinical variables, such as sex, age, glioma histologic grade, treatment status (pre- vs. posttreatment), or radiation effects. We also explored a potential association between AMT uptake in nontumoral contralateral brain regions and survival.

MATERIALS AND METHODS

Subjects
Sixty-six adult patients (41 men, 25 women; mean age ± SD, 55 ± 15 y), diagnosed with unilateral World Health Organization grade III–IV...
glioma (21 grade III, 45 grade IV), underwent AMT PET imaging. Thirty-five patients were studied before treatment, within 3 wk before initial tumor resection. Forty-two patients underwent PET after initial treatment (i.e., surgery, followed by chemoradiation) because of suspicion of glioma recurrence based on serial MR images or clinical progression. Patients with poor performance status (such as a Karnofsky performance score of 50 or below) were not included. Most pretreatment patients were on prophylactic antiepileptic medication (levetiracetam in most cases), and 12 patients had at least 1 documented clinical seizure and epileptiform activity on electroencephalography before initial treatment. All these patients underwent surgical tumor resection, followed by chemoradiation. Posttreatment patients were taking temozolomide after the completion of radiotherapy until radiographic tumor progression. The time between completion of initial radiotherapy and the PET scan was below 5 y in all but 2 patients (2 mo–4.5 y; median, 1.2 y); 2 patients (with grade III glioma) underwent their initial radiotherapy 6.7 and 11.6 y before the AMT PET. Second-line therapy after the AMT PET scan included bevacizumab with or without irinotecan (n = 16) or second surgery (n = 14). Eleven patients underwent both pre- and posttreatment AMT PET scans; thus, 77 AMT PET scans were analyzed. Of the patients with grade III glioma, 6 had 1p/19q deletion; isocitrate dehydrogenase 1 mutation was not available in all patients, particularly those studied several years ago. The study was approved by the Institutional Review Board of Wayne State University, and all subjects signed a written informed consent form.

AMT PET Scanning Protocol

AMT PET images were acquired using an EXACT/HR whole-body positron emission tomograph (Siemens Medical Systems). AMT was synthesized using a high-yield procedure (21). The procedure for AMT PET scanning has been described in detail previously (9,22,23). Briefly, after 6 h of fasting 3.7 MBq of AMT per kilogram were injected. Coinciding with tracer injection, a dynamic PET scan of the heart was acquired to obtain the blood input function from the left cardiac ventricle. The blood input function was continued using venous blood samples (0.5 mL/sample, collected at 20, 30, 40, 50, and 60 min after AMT injection) (9). At 25 min after tracer injection, a dynamic emission scan of the brain (7 × 5 min) was obtained. Measured attenuation correction, scatter, and decay correction were applied. All images were reconstructed with filtered backprojection using a Hanning filter, yielding images with an in-plane resolution of 7.5 ± 0.4 mm in full width at half maximum and 7.0 ± 0.5 mm in full width at half maximum in the axial direction. Primary image analysis was performed using AMT standardized uptake value (SUV) images, because venous blood samples for blood input function were not available in 9 patients. The SUV was calculated by dividing the average tracer concentration in tissue at 30–55 min by the ratio of injected activity and injected mass. The SUVs were calculated by dividing the average tracer concentration in tissue at 30–55 min by the ratio of injected activity and injected mass. The SUVs for each ROI were quantified as well as thalamocortical ratios. PET variables found to be significant predictors in the univariate analyses were then entered in multivariate Cox regression analyses along with clinical predictors that showed significance or a trend (P < 0.1) in the univariate analysis. A similar analysis was also performed to determine the prognostic value of AMT uptake when the mean tumor SUV (a previously reported predictor of posttreatment survival (11)) was also included as a predictor.

To explore whether radiation could have affected nontumoral AMT uptake, we correlated AMT SUVs in the nontumoral hemisphere and the time elapsed between completion of radiation and the posttreatment PET scan using Pearson correlation; we have also examined the scatterplots for nonlinearity. Because the thalamus was often located

AMT PET/MR fusion images of patient with right insular glioma. Contralateral frontal (A), thalamic (B), and temporal (C) ROIs used for analyses are outlined in red.

Statistical Analysis

To explore whether radiation could have affected nontumoral AMT uptake, we correlated AMT SUVs in the nontumoral hemisphere and the time elapsed between completion of radiation and the posttreatment PET scan using Pearson correlation; we have also examined the scatterplots for nonlinearity. Because the thalamus was often located
within the field of radiation, we also measured the radiation dose absorbed by the thalamus of the nontumoral hemisphere of high-grade glioma patients who received radiation therapy in our institution before the AMT PET (n = 23). We used the Eclipse Treatment Planning Workstation 8.9 (Varian Medical Systems) to load the original radiation plans and segment the thalami, and then we quantified the maximum radiation dose absorbed in this region. For the patients whose thalami received at least 20% of the total tumoral radiation (i.e., >10–12 Gy; n = 20), we correlated the thalamic dose with the thalamic and cortical AMT parameters using Pearson correlation. We also evaluated whether the radiation dose to the thalamus had an effect on survival using a Cox regression analysis in this subgroup.

Finally, we compared pre- and posttreatment cortical and thalamic AMT SUV in the 11 patients who were scanned both before and after glioma treatment, using the Wilcoxon test; because these comparisons showed no significant results (or even trends), these data are not included in the “Results” section. All statistical analyses were performed using SPSS Statistics 20.0 (SPSS). A P value of less than 0.05 was considered statistically significant.

RESULTS

Effects of Age, Sex, and Glioma Histologic Grade

Pretreatment thalamic SUVs showed a moderate increase with age (r = 0.39, P = 0.02), whereas the posttreatment group showed a trend for age-related decline in the thalamic K values (r = −0.33, P = 0.057). In sex comparisons, AMT SUVs and K values were generally higher in women in both the cortex and the thalamus, with the following differences reaching statistical significance: thalamic SUV in the pretreatment group (3.0 ± 0.8 vs. 2.5 ± 0.5, P = 0.037) as well as AMT K values in the thalamus (P = 0.013) and in the frontal cortex (P = 0.023) in the posttreatment group. Grade III versus IV glioma patients showed no thalamic or cortical AMT uptake differences in pretreatment patients. In the posttreatment group, thalamic AMT SUV was slightly higher in patients with grade IV than those with grade III glioma (3.0 ± 0.7 vs. 2.6 ± 0.6, P = 0.045).

Thalamic and Cortical AMT Uptake and Survival in Patients with High-Grade Glioma

In the pretreatment group of patients, none of the AMT PET parameters were prognostic for survival in Cox regression analyses. In the posttreatment group, univariate Cox regression analyses (Table 1) showed that high thalamocortical ratios (particularly values above 1.19; Fig. 2) and, to a lesser degree, high thalamic and frontal SUV were all prognostic for poor survival. Among the clinical predictors, higher glioma grade and short time between radiotherapy and AMT PET were prognostic for poor survival. Higher age was only marginally prognostic for poor survival. In multivariate Cox regression (Table 2), the thalamocortical SUV ratios remained strongly prognostic when age, glioma histologic grade, time between radiotherapy and PET, or mean tumoral SUV were added as a second (clinical) prognostic variable to the model. The thalamic SUVs remained significant when age, interval between radiotherapy, and PET but not when glioma grade or tumoral SUV were added to the model. The frontal SUVs were prognostic only when age was added to the model (Table 2).

Table 1

<table>
<thead>
<tr>
<th>Effect</th>
<th>HR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalamic SUV</td>
<td>2.23 (1.3–3.8)</td>
<td>0.004*</td>
</tr>
<tr>
<td>Frontal cortical SUV</td>
<td>2.01 (1.01–4.4)</td>
<td>0.047*</td>
</tr>
<tr>
<td>Temporal cortical SUV</td>
<td>1.90 (0.99–3.6)</td>
<td>0.052</td>
</tr>
<tr>
<td>Thalamocortical SUV ratio</td>
<td>2.544 (43–149,205)</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Tumoral SUV</td>
<td>1.57 (1.18–2.10)</td>
<td>0.002*</td>
</tr>
</tbody>
</table>

TABLE 1
Results of Univariate Cox Regression Analyses for Potential Predictors of Survival in Posttreatment Group (n = 42)

*P value is significant.

HR = hazard ratio; CI = confidence interval.

Both AMT PET variables and clinical predictors were tested for prediction of survival after PET scan. Note high HR and low P values for thalamocortical ratios; extremely high HR values partly reflect limited range of this variable (1.09–1.55 for this subgroup), thus, full unit difference (e.g., from 1 to 2) between 2 individuals would be associated with extremely different risk for death.

Relationship Between Radiation Exposure and Contralateral AMT Uptake

In the whole group, both thalamic SUVs and thalamocortical SUV ratios showed a negative correlation with the time between radiotherapy, but this correlation was nonsignificant when linear (Pearson) correlation was applied; however, the scatterplots suggested a logarithmic relationship, which was significant for both thalamic SUVs (r = 0.33, P = 0.035) and the thalamocortical ratios (r = −0.44, P = 0.004). This negative relation was also observed in the glioblastoma subgroup (thalamocortical: r = 0.46, P = 0.011; thalamic SUV: r = −0.4, P = 0.054).

The maximum thalamic radiation doses (range, 1.3–60.9 Gy; mean, 44.0 Gy) showed an inverse correlation with cortical and thalamic SUVs, which was significant only for the cortex (frontal: r = −0.49, P = 0.03; temporal: r = −0.45, P = 0.047; thalamus: r = −0.29;
The reason for the prognostic value of the thalamic and cortical SUV (and also SUV ratios) in the posttreatment group remains to be determined. Possible explanations include the presence of infiltrative glioma cells in distant brain regions (27) or upregulation of the inflammatory kynurenine pathway in these regions, perhaps induced by glioma-associated cytokines (28). In the ipsilateral hemisphere, we have recently shown that glioma-infiltrated brain can indeed show increased AMT uptake even if conventional MR imaging shows no abnormalities (10). Regardless of the mechanisms, the strong prognostic value of thalamic AMT SUV in the posttreatment group may indicate a link between extratumoral amino acid metabolism and survival. The association of high thalamocortical SUV ratios and short survival remained significant even when several clinical predictors or tumor SUVs were entered in multivariate regressions. Thus, thalamic SUV and thalamocortical SUV ratio may complement other prognostic variables for predicting survival after initial treatment. The practical advantage of measuring extratumoral tracer uptake is that measurements in the contralateral hemisphere can be obtained in a more standardized way than measurements from heterogeneous posttreatment changes suspicious for tumor recurrence. SUV is a simple, practical uptake measure, which has been shown to correlate with AMT K values, although the latter parameter is more intimately related to serotonin synthesis. However, measurement of AMT K is not practical in the clinical setting because it requires invasive blood sampling.

In addition to the prognostic value discussed above, some interesting sex differences as well as effects of radiation on contralateral tryptophan uptake deserve discussion. The slightly higher values in women might be related to physiologic sex differences in brain serotonin synthesis. Indeed, a previous AMT PET study from our group reported 10%–20% higher serotonin synthesis rates in healthy women than men (2). A subsequent smaller study from the Montreal group, applying an objective, voxel-by-voxel comparison, found a more complex pattern, with region-specific sex differences (16). However, the same group published data from a larger healthy cohort (n = 59), in which men showed higher AMT trapping in multiple cortical regions with no subcortical differences (29). In the present study, the sex differences in AMT K values were more pronounced and widespread (present both in the thalamus and in the cortex) in the posttreatment group, possibly indicating serotonergic

<table>
<thead>
<tr>
<th>Covariate added to Cox regression</th>
<th>AMT PET predictors</th>
<th>Age</th>
<th>Glialoma grade</th>
<th>Time since radiotherapy</th>
<th>Tumor SUV</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR (95% CI)</td>
<td>P</td>
<td>HR (95% CI)</td>
<td>P</td>
<td>HR (95% CI)</td>
<td>P</td>
</tr>
<tr>
<td>Thalamic SUV</td>
<td>2.2 (1.3–3.8)</td>
<td>0.005*</td>
<td>1.6 (0.9–2.9)</td>
<td>0.1</td>
<td>1.9 (1.1–3.3)</td>
</tr>
<tr>
<td>Frontal SUV</td>
<td>2.2 (1.04–4.6)</td>
<td>0.04*</td>
<td>1.5 (0.7–3.3)</td>
<td>0.29</td>
<td>1.9 (0.95–3.9)</td>
</tr>
<tr>
<td>Thalamocortical SUV ratio</td>
<td>1776 (25–122,730)</td>
<td>0.001*</td>
<td>597 (6.3–56,621)</td>
<td>0.005*</td>
<td>329 (4–25,649)</td>
</tr>
</tbody>
</table>

*P value is significant.

HR = hazard ratio; CI = confidence interval.

Clinical variables and mean tumoral SUV were entered as covariates for each of the contralateral AMT predictors found significant in univariate analysis. Hazard ratios are given for AMT PET predictors after addition of each covariate to model. Thalamocortical AMT SUV ratio remained highly prognostic for survival with each of the covariates.
changes, especially in women, after glioma therapy. The clinical sig-
nificance of these remains to be clarified. One plausible clinical im-
plication of brain serotonergic changes involves anxiety and depression,
common comorbidities in glioma patients (30,31), with a potentially
higher incidence in women (32). Thus, AMT PET could be a useful
imaging modality to clarify the role of abnormal brain serotonin
synthesis, and their sex differences, in glioma-associated depression.

The age-related results are partly consistent with a previous
AMT PET study of healthy subjects showing no age-related changes
in serotonin synthesis rates in the cortex or in the subcortical gray
matter (14). In our present study, we also did not detect robust age-
related variations, except a mild thalamic increase in the pretreat-
ment and decline in the posttreatment subgroup. One possible ex-
planation is that treatment, which typically included both local and
systemic therapy, induced neuronal loss, and this effect may be
more severe in older patients with longer treatment history; ra-
diotherapy is known to cause chronic, progressive pathologic changes
extending outside the tumor region (33). Direct thalamic radiation
effects may play a role in the observed age-related decline. Al-
though radiation dose to the thalamus did not have a significant
effect on thalamic AMT uptake, radiation may reduce cortical
tryptophan uptake in a dose-dependent manner. On the other hand,
thalamic tryptophan uptake was lower in those with longer sur-
vival after radiation treatment. Therefore, it is likely that chronic,
progressive brain tissue damage after initial radiation contributed
to lower values in older posttreatment patients.

Despite the relatively large cohort of glioma patients, our study
had some limitations. The analysis was retrospective, and patients
in the posttreatment group were scanned at different times after
initial treatment. The patients also received variable treatments
after the PET scan: for example, some underwent repeated surgery
or received antiangiogenic treatment with bevacizumab. How-
ever, in our recent study, repeated surgery or bevacizumab
therapy after AMT PET were not prognostic (11); also, a recently
concluded large bevacizumab trial found no robust drug effects on
overall survival (34). Thus, postscan therapy was unlikely to have
a major effect on the prognostic results. Another potential prog-
nostic factor of posttreatment survival is performance status. We
did not include this factor as a potential predictor, as reliable data
were not always available at the time of the PET scan because of
the retrospective nature of the study. However, performance status
was unlikely to have a robust impact on survival in this group,
considering that patients with poor functional status (typically a
Karnofsky performance score <60) were not included in the re-
search PET studies. Likewise, we did not include some molecular
markers (such as isocitrate dehydrogenase 1 mutations) in the
analysis, because of the lack of complete dataset in this regard.
On the basis of the present results, we are now conducting a pro-
spective study in which these potential prognostic factors will be
included. In addition, we focused on selected gray matter regions
(thalamus and frontal, temporal cortices) contralateral to the tumor.
It is possible that some other cortical regions would also show
clinical correlates. Some of these regions, including brain structures
involved in serotonergic networks, may be important to study
to clarify the relevance of the findings for depression or other
glioma-related comorbidities in future studies.

CONCLUSION

In this study, we found posttreatment age-related decline and
sex differences in brain tryptophan uptake, present mostly in subjects
with a previously treated glioma. Thalamic uptake changes of the
nontumoral hemisphere were highly prognostic for posttreatment
survival. These findings suggest altered tryptophan metabolism in
the nontumoral brain, with potentially important clinical implications
for prognosis and comorbidities affecting the serotonergic system.

DISCLOSURE

The costs of publication of this article were defrayed in part
by the payment of page charges. Therefore, and solely to indicate
this fact, this article is hereby marked “advertisement” in accor-
dance with 18 USC section 1734. The study was supported by a
grant (R01 CA123451) from the National Cancer Institute; a grant
from the Fund for Medical Research and Education, Wayne State
University School of Medicine; and a Strategic Research Initiative
grant from the Karmanos Cancer Institute. No other potential
conflict of interest relevant to this article was reported.

ACKNOWLEDGMENTS

We thank Janet Barger, Kelly Forucci, and Cathie Germain for
assisting with patient recruitment and scheduling. We are grateful
to the entire staff at the PET Center, Children’s Hospital of Mich-
igan, who provided invaluable technical help in performing the PET
scans.

REFERENCES

1. Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL. A new method to measure
brain serotonin synthesis in vivo. I. Theory and basic data for a biological model.
2. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT. Human brain
3. Diksic M, Young SN. Study of the brain serotonergic system with labeled
5. Zitron IM, Kamson DO, Kioussis S, Juhasz C, Mittal S. In vivo metabolism of
tryptophan in meningiomas is mediated by indoleamine 2,3-dioxygenase 1. Cancer
7. Wainwright DA, Balysnakivova IV, Chang AL, et al. IDO expression in brain
tumors increases the recruitment of regulatory T cells and negatively impacts
8. Mitsuka K, Kawataki T, Satoh E, Ashara T, Horikoshi T, Kinouchi H. Expres-
sion of indoleamine 2,3-dioxygenase and correlation with pathological malignancy
26:345–357.
in pre and post-treatment gliomas. Neuro Oncol. April 1, 2014 [Epub ahead of print].
MRI and PET imaging for assessment of treatment response in patients with
regional o-[11C]methyl-L-tryptophan trapping, used as an index of 5-HT synthesis,


Clinical Significance of Tryptophan Metabolism in the Nontumoral Hemisphere in Patients with Malignant Glioma


Published online: September 4, 2014.
Doi: 10.2967/jnumed.114.141002

This article and updated information are available at:
[http://jnm.snmjournals.org/content/55/10/1605](http://jnm.snmjournals.org/content/55/10/1605)

Information about reproducing figures, tables, or other portions of this article can be found online at:
[http://jnm.snmjournals.org/site/misc/permission.xhtml](http://jnm.snmjournals.org/site/misc/permission.xhtml)

Information about subscriptions to JNM can be found at:
[http://jnm.snmjournals.org/site/subscriptions/online.xhtml](http://jnm.snmjournals.org/site/subscriptions/online.xhtml)